Merrill reiterates OSI at buy

OSI Pharmaceuticals, Inc. was reiterated at a buy by Merrill Lynch analyst Eric Ende. Roche reported ex-U.S. Tarceva sales of $53 million, in line with the analyst's $53.2 million, and above consensus estimate of $48 million. Management could announce sharp expense reductions for its eye business, in light of potentially weak Macugen sales on pressure from Lucentis. It is possible that OSI could be sold, according to the analyst. Shares of the Melville, N.Y.-based pharmaceutical company were down $1.13, or 3.51%, at $31.10 on volume of 920,900 shares versus the three-month running average of 1,153,600 shares. (Nasdaq: OSIP)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.